Why the study?
Patients with rheumatic diseases face high cardiovascular risk due to inflammation, requiring a comprehensive understanding of underlying mechanisms and accurate risk assessment to guide rational, safe treatment.
This review highlights the mechanisms linking chronic inflammation in rheumatic diseases to accelerated cardiovascular risk and emphasizes the need for accurate risk assessment.
Patients suffering from rheumatic diseases are at high risk of the development and accelerated progression of cardiovascular due to inflammation as one of the etiological factors of atherogenesis and heart failure. To choose the rational and safe treatment, especially in comorbid patients, it is necessary to have a comprehensive and complete understanding of the mechanisms of these relationships, as well as the most accurate determination of cardiovascular risk using modern validated scales. The first part of the review presents the results of current experimental and clinical studies on the effect of the chronic inflammatory and its biomarkers on the development, course and prognosis of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2024) conducted a review in Rheumatic diseases and cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: